



## Identify high-risk drug prescribing, billing and dispensing to combat fraud

### Risks posed by social groups

Numerous schemes fuel a growing prescription drug fraud epidemic that wastes billions of dollars and endangers millions of lives. While opioids have garnered much of the attention in recent years, prescription drug fraud goes far beyond the headlines about controlled drugs. Fraudsters also target high-dollar drugs, such as those often used to treat HIV, mental health, diabetes and cancer.

Although no single path exists to thwart this crisis, big data and analytics can help you to identify social groups that may be perpetrating prescription drug fraud schemes. These clusters or networks may consist of friends, family members, business colleagues and associates, among others. Working together, they seek to obtain, abuse, resell or otherwise divert prescription drugs, putting any entity interacting with them—be they other patients, providers, pharmacies or even payers—at risk.



## LexisNexis® Drug Socialization™

LexisNexis® Drug Socialization™\* is the newest extension of the LexisNexis® Relationship Mapping solution. It leverages advanced analytics, linking and visualization to help healthcare organizations uncover significant unknown and risky connections.

Utilizing LexisNexis® referential provider, identity and claims data in combination with customer data, our clients can:

- Visualize unknown social relationships
- Identify key players and connections
- Gain insight into frequently missed patterns of behavior
- Detect non-network individuals and/or entities
- Simplify understanding of criminal organizational hierarchies

By evaluating relationships outside of the normal scope of healthcare data and leveraging outside data assets from disparate sources, you can now recognize and understand drug-related social groups and the risk they represent to your patients and organization.




### Recognize suspicious entities

LexisNexis® Drug Socialization™ links together prescribers, pharmacies and patients through unusual prescribing habits, aberrant dispensing patterns and drug seeking behavior.



Built into the analytic models are factors such as claim history, social nature of the drug, geographic distribution and the relationships among the entities. Overlaying linking analysis to internal and external data sources can then expose potential drug misuse.



## LexisNexis® Drug Socialization™ finds:

**HIGH-RISK CLUSTERS** – unusual groups of interconnected members receiving the same drug

- Unusual either due to size or other aggregated attributes
- Example: over-prescribing “non-social” drugs to wide social group

**SOCIAL PRESCRIBERS** – prescribes into an unusually large number of social groups

- May be knowingly or unknowingly part of a scheme
- Example: doctor pill shopping; street sales via pharmacy

**SOCIAL DISPENSERS** – pharmacies dispensing into unusually large number of social groups

- May be knowingly or unknowingly part of a scheme
- Example: pharmacy over-dispensing



By mapping relatives and associates, LexisNexis® Drug Socialization™ enables you to identify the social groups to which high-risk entities belong. As social groups are identified, each high-risk member of that social group draws greater attention to the risk represented by the whole. As such, bad actors whom you might otherwise not notice, suddenly become obvious participants in an organized scheme.



## Gain insight into emerging risks

LexisNexis® Drug Socialization™ helps you answer important questions about individuals in suspicious social groups such as:

### SOCIALIZATION

- Does the patient belong to a network of patients receiving the same drug type?
- Is a single prescriber predominantly servicing these high-risk patients?

### PILL MILLS

- Does the prescriber or pharmacy have high percentages of patients treating/filling high-risk drugs?

### FREQUENT FLIERS/DOCTOR SHOPPERS

- Is the patient receiving multiple prescriptions within a short timeframe either from one or many prescribers or pharmacies?

### UNSAFE MEDICATIONS

- Is the patient receiving a prescription that exceeds the recommended daily safe medication?
- Are people within a specific network receiving excessive medications or drug types?
- Does the prescriber have a high rate of prescribing over the daily medication?

With answers to these questions about suspicious social groups, you can more quickly detect and mitigate fraud.

Insights into suspicious social groups can inform unprecedented decision-making and help you clearly see emerging risks.



## Discover the value of LexisNexis® Drug Socialization™

LexisNexis® Drug Socialization™ provides actionable insights into connections that were previously hidden, helping you to:

- Uncover collusive opioid or other drug-related relationships and schemes quickly
- Expand case size by revealing full scope of scheme and all suspects
- Increase efficiency by identifying cases with largest potential ROI
- Save time and boost productivity by reducing your manual investigative effort

LexisNexis® Drug Socialization™ can offer a unique view of individuals as they engage various providers throughout the healthcare system. By exposing risk factors and behaviors that are often indicative of drug abuse, you now have the tools to better prevent, detect and collaborate in stopping prescription drug fraud.

For more information, call 866.396.7703 or visit  
[risk.lexisnexis.com/products/relationship-mapping](http://risk.lexisnexis.com/products/relationship-mapping)



Health Care

### About LexisNexis® Risk Solutions

LexisNexis Risk Solutions harnesses the power of data and advanced analytics to provide insights that help businesses and governmental entities reduce risk and improve decisions to benefit people around the globe. We provide data and technology solutions for a wide range of industries including insurance, financial services, healthcare and government. Headquartered in metro Atlanta, Georgia, we have offices throughout the world and are part of RELX Group (LSE: REL/NYSE: RELX), a global provider of information and analytics for professional and business customers across industries. RELX is a FTSE 100 company and is based in London. For more information, please visit [www.risk.lexisnexis.com](http://www.risk.lexisnexis.com) and [www.relx.com](http://www.relx.com).

Our healthcare solutions combine proprietary analytics, science and technology with the industry's leading sources of provider, member, claims and public records information to improve cost savings, health outcomes, data quality and compliance and minimize exposure to fraud, waste and abuse.

\*The LexisNexis® Drug Socialization™ module is an iterative solution and the relevant scope of product and deliverables are determined on a client-by-client basis.

Drug Socialization™ provided by LexisNexis is not provided by "consumer reporting agencies" as that term is defined in the Fair Credit Reporting Act (15 U.S.C. § 1681, et seq.) ("FCRA") and does not constitute a "consumer report" as that term is defined in the FCRA. Drug Socialization™ may not be used in whole or in part as a factor in determining eligibility for credit, insurance or employment or for any other eligibility purpose that would qualify it as a consumer report under the FCRA. Due to the nature and origin of public record information, the public records and commercially available data sources used in reports may contain errors. Source data is sometimes reported or entered inaccurately, processed poorly or incorrectly, and is generally not free from defect. This product or service aggregates and reports data, as provided by the public records and commercially available data sources, and is not the source of the data, nor is it a comprehensive compilation of the data. Before relying on any data, it should be independently verified.

LexisNexis and the Knowledge Burst logo are registered trademarks of RELX Inc. Drug Socialization™ is a trademark of LexisNexis Risk Solutions. Other products and services may be trademarks or registered trademarks of their respective companies. Copyright © 2018 LexisNexis. All rights reserved. NXR12570-00-1018-EN-US